Endocrine Abstracts

Introduction

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a new class of oral antidiabetic drugs used for the treatment of type 2 diabetes mellitus. Recently, the SGLT2i dapagliflozin was approved for use in type 1 diabetes (T1DM) as an add-on to insulin therapy.

Material and methods

We conducted a retrospective observational study which included demographic and clinical-analytical data from 16 patients with T1DM that started dapagliflozin at a dosage of 10 mg/day. Our purpose was to assess the effect of dapagliflozin six months after its initiation.

Resultados

Data were analyzed from 16 patients with T1DM, 10 women and 6 men, 41.2 ± 14.8 years old, 22.7 ± 14.7 years of diabetes duration. 3 of the participants presented high blood pressure. With regard to diabetic complications, 4 patients had retinopathy, 1 nephropathy, 1 neuropathy, 1 ischemic cardiomyopathy. Basal characteristics of the participants: BMI 32.4 ± 6 kg/m²; weight 91.1 ± 16.7 kg; HbA1c 8.1 ± 0.8%; blood pressure 129.8 ± 23.1/77.8 ± 11.12 mm Hg; basal insulin dose 46.7 ± 24.2 IU, prandrial insulin dose 34.8 ± 16 IU. 5 of the participants were on treatment with metformin. Six months after the initiation of dapagliflozin, significant reductions in BMI (30.7 ± 6.4 kg/m²), weight (86.9 ± 18.2 kg), HbA1c (7.5 ± 0.7%), basal insulin requirements (44.3 ± 25 IU) and prandrial insulin requirements ((29.6 ± 15.2 IU) were observed. There were no significant differences with respect to blood pressure. Two patients discontinued dapagliflozin because of recurrent urinary tract infections.

Conclusion

The use of dapagliflozin in patients with T1DM was associated with an improvement of metabolic control, weight loss and reduction of insulin requirements, without severe side effects.